The effect of doxorubicin incorporated into a phospholipid delivery nanosystem on HepG2 cells proteome
- 45 Downloads
A phospholipid drug delivery nanosystem with particle size up to 30 nm elaborated at the Orekhovich Institute of Biomedical Chemistry (Russian Academy of Medical Sciences) has been used earlier for incorporation of doxorubicin (Doxolip). This system demonstrated higher antitumor effect in vivo as compared with free doxorubicin. In this study the effect of this nanosystem containing doxorubicin on HepG2 cell proteome has been investigated. Cells were incubated in a medium containing phospholipid nanoparticles (0.5 μg/mL doxorubicin, 10 μg/mL phosphatidylcholine). After incubation for 48 h their survival represented 10% as compared with untreated cells. Cell proteins were analyzed by quantitative two-dimensional gel electrophoresis followed by identification of differentially expressed proteins with MALDI-TOF mass spectrometry. The phospholipid transport nanosystem itself insignificantly influenced the cell proteome thus confirming previous data on its safety. Doxorubicin, as both free substance and Doxolip (i.e., included into phospholipid nanoparticles) induced changes in expression of 28 proteins. Among these proteins only four of them demonstrated different in response to the effect of the free drug substance and Doxolip. Doxolip exhibited a more pronounced effect on expression of certain proteins; the latter indirectly implies increased penetration of the drug substance (included into nanoparticles) into the tumor cells. Increased antitumor activity of doxorubicin included into phospholipid nanoparticles may be associated with more active increase of specific protein expression.
Keywordsphospholipid nanoparticles proteome doxorubicin HepG2 cells MALDI-TOF mass spectrometry
Unable to display preview. Download preview PDF.
- 2.Archakov, A.I., Biomed. Khim., 2010, vol. 56, pp. 7–25.Google Scholar
- 6.Agrawal, G.K., Timperio, A.M., Zolla, L., Bansal, V., Shukla, R., and Rakwal, R., J. Proteomics, 2013, Apr. 22. pii: S1874–3919 [Epub ahead of print].Google Scholar
- 8.Rafati, H. and Mirzajani, F., Pharmazie, 2011, vol. 66, no. 1, pp. 31–36.Google Scholar
- 9.Archakov, A.I., Guseva, M.K., Uchaikin, V.F., Ipatova, O.M., Tikhonova, E.G., Medvedeva, N.V., Lisitsa, A.V., Prozoroskii, V.N., Strekalova, O.S., and Shironin, A.V., Rus Patent no. 2391966, Byul. Izobret., 2010, no. 17.Google Scholar
- 10.Ipatova, O.M., Prozorovskiy, V.N., Medvedeva, N.V., Shironin, A.V., Strekalova, O.S., Ivanova, N.D., Torkhovskaya, T.I., and Archakov, A.I., Eur. Congress for Drug Discovery (MipTec), 2010, Basel, Abstr. 80.Google Scholar
- 11.Archkov, A.I., Ipatova, O.M., Medvedeva, N.V., Prozoroskii, V.N., Torkhovskaya, T.I., Tikhonova, E.G., Zykova, M.G., and Voskresenskaya, A.A., Rus. Patent no. 2411935, Byul. Izobret., 2011, no. 5.Google Scholar
- 12.Zykova, M.A., Ipatova, O.M., Prozorovskii, V.N., Medvedeva, N.V., Voskresenskaya, A.A., Zakharova, T.S., and Torkhovskaya, T.I., Biomed. Khim., 2011, vol. 57, pp. 174–179.Google Scholar
- 13.Zykova, M.A., Medvedeva, N.V., Torkhovskaya, T.I., Tikhonova, E.G., Prozorovskii, V.N., Zakharova, T.S., and Ipatova, O.M., Exp. Oncol., 2012, vol. 34, no. 4, pp. 323–326.Google Scholar
- 17.O’Farrell, P., J. Biol. Chem., 1975, vol. 250, pp. 4007–4021.Google Scholar